234 related articles for article (PubMed ID: 16411063)
1. Pathogenesis of prolactinomas.
Spada A; Mantovani G; Lania A
Pituitary; 2005; 8(1):7-15. PubMed ID: 16411063
[TBL] [Abstract][Full Text] [Related]
2. Pituitary prolactin-secreting tumor formation: recent developments.
Xu RK; Wu XM; Di AK; Xu JN; Pang CS; Pang SF
Biol Signals Recept; 2000; 9(1):1-20. PubMed ID: 10686432
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses.
Evans CO; Moreno CS; Zhan X; McCabe MT; Vertino PM; Desiderio DM; Oyesiku NM
Pituitary; 2008; 11(3):231-45. PubMed ID: 18183490
[TBL] [Abstract][Full Text] [Related]
4. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics.
Gürlek A; Karavitaki N; Ansorge O; Wass JA
Eur J Endocrinol; 2007 Feb; 156(2):143-53. PubMed ID: 17287403
[TBL] [Abstract][Full Text] [Related]
5. ras mutations in human prolactinomas and pituitary carcinomas.
Cai WY; Alexander JM; Hedley-Whyte ET; Scheithauer BW; Jameson JL; Zervas NT; Klibanski A
J Clin Endocrinol Metab; 1994 Jan; 78(1):89-93. PubMed ID: 8288721
[TBL] [Abstract][Full Text] [Related]
6. Genetic basis of pituitary adenoma invasiveness: a review.
Suhardja A; Kovacs K; Rutka J
J Neurooncol; 2001 May; 52(3):195-204. PubMed ID: 11519849
[TBL] [Abstract][Full Text] [Related]
7. Growth factors in the pathogenesis of prolactin-secreting tumors.
Missale C; Spano PF
J Endocrinol Invest; 1998 Jun; 21(6):402-11. PubMed ID: 9699134
[No Abstract] [Full Text] [Related]
8. Relationship between expression of vascular endothelial growth factor and the proliferation of prolactinomas.
Li N; Jiang Z
Clin Neurol Neurosurg; 2017 Feb; 153():102-106. PubMed ID: 28110235
[TBL] [Abstract][Full Text] [Related]
9. Enhanced LH action in transgenic female mice expressing hCGbeta-subunit induces pituitary prolactinomas; the role of high progesterone levels.
Ahtiainen P; Sharp V; Rulli SB; Rivero-Müller A; Mamaeva V; Röyttä M; Huhtaniemi I
Endocr Relat Cancer; 2010 Sep; 17(3):611-21. PubMed ID: 20453081
[TBL] [Abstract][Full Text] [Related]
10. Molecular screening of pituitary adenomas for gene mutations and rearrangements.
Herman V; Drazin NZ; Gonsky R; Melmed S
J Clin Endocrinol Metab; 1993 Jul; 77(1):50-5. PubMed ID: 8100831
[TBL] [Abstract][Full Text] [Related]
11. Ras mutations in human pituitary tumors.
Karga HJ; Alexander JM; Hedley-Whyte ET; Klibanski A; Jameson JL
J Clin Endocrinol Metab; 1992 Apr; 74(4):914-9. PubMed ID: 1312542
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel somatic mutation of POU6F2 by whole-genome sequencing in prolactinoma.
Miao Y; Li C; Guo J; Wang H; Gong L; Xie W; Zhang Y
Mol Genet Genomic Med; 2019 Dec; 7(12):e1022. PubMed ID: 31692290
[TBL] [Abstract][Full Text] [Related]
13. Genetics of pituitary tumors: Focus on G-protein mutations.
Lania A; Mantovani G; Spada A
Exp Biol Med (Maywood); 2003 Oct; 228(9):1004-17. PubMed ID: 14530508
[TBL] [Abstract][Full Text] [Related]
14. Hormonal signaling and pituitary adenomas.
Spada A; Lania A; Mantovani G
Neuroendocrinology; 2007; 85(2):101-9. PubMed ID: 17337884
[TBL] [Abstract][Full Text] [Related]
15. Genetic aspects of pituitary tumors.
Spada A
J Pediatr Endocrinol Metab; 2001; 14 Suppl 5():1213-6; discussion 1261-2. PubMed ID: 11964015
[TBL] [Abstract][Full Text] [Related]
16. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
Gao H; Wang F; Lan X; Li C; Feng J; Bai J; Cao L; Gui S; Hong L; Zhang Y
BMC Cancer; 2015 Apr; 15():272. PubMed ID: 25884948
[TBL] [Abstract][Full Text] [Related]
17. Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred.
Burgess JR; Shepherd JJ; Parameswaran V; Hoffman L; Greenaway TM
J Clin Endocrinol Metab; 1996 Jul; 81(7):2642-6. PubMed ID: 8675591
[TBL] [Abstract][Full Text] [Related]
18. Transforming DNA sequences present in human prolactin-secreting pituitary tumors.
Gonsky R; Herman V; Melmed S; Fagin J
Mol Endocrinol; 1991 Nov; 5(11):1687-95. PubMed ID: 1779971
[TBL] [Abstract][Full Text] [Related]
19. Mutational analysis of transforming growth factor-beta receptor type II and Smad3 tumor suppressor genes in prolactinomas.
Ikeda H
Brain Tumor Pathol; 2006 Apr; 23(1):7-12. PubMed ID: 18095113
[TBL] [Abstract][Full Text] [Related]
20. Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation.
Lania AG; Ferrero S; Pivonello R; Mantovani G; Peverelli E; Di Sarno A; Beck-Peccoz P; Spada A; Colao A
J Clin Endocrinol Metab; 2010 Jan; 95(1):13-7. PubMed ID: 19890024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
